Agios Pharma to discontinue sickle cell disease treatment development

Agios pares loss after abandoning sickle cell asset tebapivat (AGIO:NASDAQ)

Agios halts tebapivat after phase 2 sickle cell trial; stock dips as focus shifts to mitapivat sNDA. Read more here.

Agios scraps sickle cell drug

The study failure costs Agios a chance to one-up Novo Nordisk and represents yet another setback in a disease that’s frustrated drugmakers of late.

Agios Pharma to discontinue sickle cell disease treatment development

July 21 (Reuters) - Agios Pharmaceuticals said on Tuesday it will ​stop development of ‌its sickle cell disease treatment, sending its shares down 14% in premarket ‌trading. The ​trial ⁠was designed to ⁠characterize the dose-response relationship of th...

Agios’ second shot at sickle cell disease falls short

Agios said it is dropping a next-generation sickle cell disease drug after lackluster results from a mid-stage trial. The drug, known as tebapivat, represented Agios’ second shot at the disease, and its “primary opportunity to ...